Contribute Try STAT+ Today

WASHINGTON — For a pharmaceutical industry that has spent two years sparring with health secretary Alex Azar, a former Eli Lilly executive fixated on the issue of high drug prices, President-elect Biden’s pick for the role, Xavier Becerra, may seem like incredible news. In his health policy work, Becerra has focused far more on Obamacare and health disparities than on the high price of medicines.

But one of Becerra’s earliest potential policy decisions might inflict more pain on the drug industry than anything Azar ever threatened.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.